{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T17:23:32Z","timestamp":1787765012305,"version":"build-2784847793"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>This cross-sectional descriptive study was conducted over 3 months (April\u2013June 2025) among acute coronary syndrome (ACS) patients who received eptifibatide at Shahid Chamran Hospital, Isfahan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Patient demographics, diagnosis, and the chosen therapeutic approach (revascularization or ischemia-guided) were collected. Data on concomitant medications (including aspirin and P2Y12 inhibitors), timing, and dosing were extracted from medical records. Details on eptifibatide administration (total dose and time) were captured. The procedural time and intra-procedural events (thrombotic events, no-reflow) were documented. The appropriateness of eptifibatide use was evaluated against European Society of Cardiology-ACS 2023 and American Heart Association-ACS 2025 guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings:<\/jats:title>\n                    <jats:p>A total of 150 patient records were reviewed. Only 48% of eptifibatide prescriptions were guideline-concordant. Of the rational prescriptions, two cases were due to intra-procedural thrombotic events, five due to no-reflow phenomena, and 65 due to insufficient time for the P2Y12 inhibitor to achieve a therapeutic effect (all received clopidogrel as the P2Y12 inhibitor) at percutaneous coronary intervention. Notably, 97.33% of patients received clopidogrel, while only 2.66% received ticagrelor, the faster-onset P2Y12 inhibitor preferred by guidelines over clopidogrel. This suggests that using ticagrelor instead of clopidogrel in these cases might have eliminated the need for eptifibatide owing to its quicker onset.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The study shows limited concordance between eptifibatide prescribing and guidelines. In addition, using ticagrelor instead of clopidogrel might eliminate the need for eptifibatide owing to its quicker onset.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jrpp.jrpp_108_25","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T04:00:23Z","timestamp":1771992023000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of the Rational use of Eptifibatide among Patients with Acute Coronary Syndrome Referred to Shahid Chamran Heart Hospital"],"prefix":"10.4103","volume":"15","author":[{"given":"Javad","family":"Amini","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacy Practice, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrnoush","family":"Dianatkhah","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacy Practice, Isfahan University of Medical Sciences, Isfahan, Iran"},{"name":"Hypertension Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahnaz","family":"Momenzadeh","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacy Practice, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeide","family":"Bahrani","sequence":"additional","affiliation":[{"name":"Hypertension Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehsan","family":"Shirvani","sequence":"additional","affiliation":[{"name":"Interventional Cardiology Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niloufar Sadat","family":"Mirasi","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacy Practice, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Heidarnezhad","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacy Practice, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,2]]},"reference":[{"key":"R1-20260225","first-page":"e38","article-title":"Heart disease and stroke statistics-2016 Update: A report from the American Heart Association","volume":"133","author":"Mozaffarian","year":"2016","journal-title":"Circulation"},{"key":"R2-20260225","article-title":"Applied therapeutics: The clinical use of drugs","author":"Zeind"},{"key":"R4-20260225","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1056\/NEJMoa1908973","article-title":"Ticagrelor or prasugrel in patients with acute coronary syndromes","volume":"381","author":"Sch\u00fcpke","year":"2019","journal-title":"N Engl J Med"},{"key":"R5-20260225","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"R6-20260225","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1016\/j.jacc.2024.11.009","article-title":"2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI Guideline for the management of patients with acute coronary syndromes: A report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"85","author":"Rao","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"R7-20260225","first-page":"55","article-title":"2023 ESC guidelines for the management of acute coronary syndromes","volume":"13","author":"Byrne","year":"2024","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"R8-20260225","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1161\/CIRCULATIONAHA.117.031164","article-title":"International expert consensus on switching platelet P2Y (12) Receptor-Inhibiting therapies","volume":"136","author":"Angiolillo","year":"2017","journal-title":"Circulation"},{"issue":"18","key":"R9-20260225","doi-asserted-by":"crossref","first-page":"2544656","DOI":"10.1080\/20523211.2025.2544656","article-title":"From prescribing indicators to rational drug use: a medication safety perspective","volume":"1","author":"Anwar","year":"2025","journal-title":"Journal of Pharmaceutical Policy and Practice"},{"key":"R10-20260225","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1093\/ajhp\/zxaa393","article-title":"ASHP guidelines on medication-use evaluation","volume":"78","author":"Afanasjeva","year":"2021","journal-title":"Am J Health Syst Pharm"},{"key":"R11-20260225","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0140-6736(11)61872-2","article-title":"Intracoronary versus intravenous bolus abciximab during primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction: A randomised trial","volume":"379","author":"Thiele","year":"2012","journal-title":"Lancet"},{"key":"R12-20260225","doi-asserted-by":"crossref","first-page":"8977","DOI":"10.3390\/ijerph19158977","article-title":"Ideal P2Y12 inhibitor in acute coronary syndrome: A review and current status","volume":"19","author":"Pradhan","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"R13-20260225","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.amjcard.2015.05.058","article-title":"Meta-analysis of comparison of the newer oral P2Y12 inhibitors (Prasugrel or Ticagrelor) to Clopidogrel in patients with non-ST-elevation acute coronary syndrome","volume":"116","author":"Bavishi","year":"2015","journal-title":"Am J Cardiol"},{"key":"R14-20260225","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1002\/clc.23654","article-title":"Glycoprotein IIb\/IIIa inhibitors use in the setting of primary percutaneous coronary intervention for ST elevation myocardial infarction in patients pre-treated with newer P2Y12 inhibitors","volume":"44","author":"Blanchart","year":"2021","journal-title":"Clin Cardiol"},{"key":"R15-20260225","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1186\/s12872-025-04767-9","article-title":"Protective effects of combined eptifibatide and ticagrelor in patients with unstable angina undergoing percutaneous coronary intervention: A single-center experience","volume":"25","author":"Shi","year":"2025","journal-title":"BMC Cardiovasc Disord"},{"key":"R16-20260225","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1002\/cpt.2055","article-title":"Clopidogrel dosing: Current successes and emerging factors for further consideration","volume":"109","author":"Chetty","year":"2021","journal-title":"Clin Pharmacol Ther"}],"container-title":["Journal of Research in Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jrpp.jrpp_108_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:54:34Z","timestamp":1787763274000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jrpp.jrpp_108_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/jrpp.jrpp_108_25","relation":{},"ISSN":["2319-9644","2279-042X"],"issn-type":[{"value":"2319-9644","type":"print"},{"value":"2279-042X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"2025-12-07","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-03","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}